Mazdutide, targeting GLP-1 and glucagon (but not GIP), reaches about 14-20% weight loss depending on dose and trial duration
Although tirzepatide has not demonstrated anabolic bone actions in animals, 57 an assessment report from the European Medicine Agency observed trends of decreased P1NP and increased CTX-I levels in people with T2D after 29 days of treatment
Figure 3 provides an integrative schematic distinguishing the indirect systemic metabolic benefits of GLP-1RAs from their direct epithelial reparative programs, highlighting where confounding by weight loss is unavoidable versus where true mucosal repair mechanisms are expected to dominate
Changes in skincare products, cosmetics, or topical treatments during the same period could influence acne independently
An eating disorder is a mental illness, not a choice that someone has made
This can be a bathroom counter, a kitchen table, or any flat surface with good lighting